Oragenics (AMEX:ONI)
Historical Stock Chart
From May 2019 to May 2024
Oragenics, Inc. d/b/a ONI Biopharma Inc. (the "Company" or "ONI"
AMEX:ONI), an American biopharmaceutical company that has developed
broad-based technologies in oral care, antibiotics, diagnostics and
weight control, today announced that commencing Monday, December 22,
2008, quotations for the Company's shares will be available on the
Over-the-Counter (OTC) Bulletin Board. To the extent a change in the
Company's trading symbol occurs the Company expects to issue a press
release announcing the new symbol. The transition to the OTC is expected
to be seamless to investors. Investors should be able to trade their ONI
shares through their brokers in the same manner as they had been prior
to this date.
Stanley B. Stein, Chief Executive Officer of ONI BioPharma commented,
“We are thrilled to be trading in two markets, the OTC and Alternext
Paris, that are best suited to biotechnology and healthcare companies.
We consider ourselves to be a global company and therefore benefit
greatly by having both a domestic and international trading presence.
Our facilities are headquartered in the US but our outreach is
worldwide. We invite you to listen to our audio release, available at
our website www.onibiopharma.com,
which will explain this in more detail and will be posted in English and
in French.”
The OTC Bulletin Board is a quotation service that displays real-time
quotes, last-sale prices and volume information in over-the-counter
securities. The Financial Industry Regulatory Authority (FINRA), a
self-regulatory organization of the securities industry in the United
States, oversees the OTC Bulletin Board. In a separate press release
issued on December 11, 2008, ONI BioPharma announced that ONI's shares
will also be traded on Alternext Paris. The new OTC Bulletin Board
listing will have no impact on the status of ONI's Alternext Paris
listing, which occurred on December 15, 2008.
The Company also announced that later today, it will post on its website
(www.onibiopharma.com)
the English version of an audio release from management that will answer
frequently-asked investor questions on the Company’s strategic plan and
the trading of its shares. The Company expects to post the French
version of the release on its website on December 23, 2008.
About ONI BioPharma
Oragenics, Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical
company with a pipeline of unique proprietary technologies, some of
which are being commercialized. The Company also has a number of
products in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases,
diagnostics, and oral health. The Company has developed platform
technologies with respect to its products, thereby creating a potential
pipeline of future products, which the Company expects to develop.
Forward-looking Statements
Safe Harbor Statement Under the Private Securities Litigation Reform Act
of 1995: This press release includes forward-looking statements that
reflect ONI BioPharma’s current views with respect to future events and
financial performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. ONI expressly disclaims any
responsibility to update forward-looking statements and draws the
attention of investors to the risk factors described in the Information
Document.
This press release does not constitute the offering of any securities
for sale. The Company's securities may not be offered or sold absent
registration under applicable securities laws or an exemption from
registration. Any public offering of the securities of the Company will
be made by means of a prospectus that will contain detailed information
about the offering and the Company.